- The trend backdrop is active with a 10-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
MOREPENLAB
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Morepen Laboratories Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
80.25 INR
40.7%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 76.9% above the Trend Line and sits at 93.6% of its 52-week range. The latest completed week returned 40.7%, after a 31.1% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 55/100. Near-term considerations: price is close to its 52-week high.
Setup score
70
out of 100
Latest Close
80.25 INR
7 Aug 2026
1W Return
40.7%
latest completed week
4W Return
31.1%
short-term follow-through
12W Return
91.3%
quarterly tape
Trend Breadth
19.2%
10 of 52 weeks active
Volume Ratio
7.3x
vs 13-week average
- Recent volatility is running well above the one-year baseline.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
40.7%
Latest completed week; four-week move 31.1%.
Indicator stack
45/76
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
55/100
19 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 76.9% above the Trend Line and sits at 93.6% of its 52-week range. The latest completed week returned 40.7%, after a 31.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 7.3x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7412-week average 0.43
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership10/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 31.1% over four weeks, 91.3% over 12 weeks, and 71.0% over one year. The current trend has remained active for 10 consecutive weeks.
Performance by holding period
Active trend streak10 weeks
Active weeks in one year10
Trend breadth19.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.45Latest activity-pressure read.
Pressure change-2.7%Four-week change in activity pressure.
Leadership76.33Latest relative-leadership reading.
RS change100.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality15/100Profitability and accounting quality. Underlying universe rank 86; rank 1 is best.
Momentum91/100Medium-term price momentum. Underlying universe rank 10; rank 1 is best.
Growth9/100Revenue and earnings growth. Underlying universe rank 92; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework11/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 46.3x Price divided by trailing earnings.
- Price / sales
- 2.4x Market value relative to trailing revenue.
- EV / EBITDA
- 26.5x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -2.8% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 37.8% Gross profit retained from each unit of revenue.
- Operating margin
- 4.9% Operating profit retained from revenue.
- Free-cash-flow margin
- -7.1% Free cash flow generated from revenue.
- Return on invested capital
- 4.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -0.3% Latest one-year revenue growth.
- EPS growth
- -19.6% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.2% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.2% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment55/100
Weighted news tone is neutral across 19 relevant articles.
2 positive · 17 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-3.9%Distance below the 52-week high.
13-week volatility12.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+40.7%Week of 7 Aug.
Worst week-8.9%Week of 6 Mar.
Latest week+40.7%Week of 7 Aug.
Shape of recent returns
Strong gains11
Modest gains5
Flat weeks0
Modest losses6
Sharp losses4
Recent vol12.2%13-week weekly-return volatility.
Base vol7.8%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -3.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank1 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank2 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape64/100
Trend, activity pressure, participation, and risk combine to a 64/100 tape read.
Indicator analysis80/100Latest 12-week confirmation: trend 10/12, activity pressure 12/12, relative leadership 10/12.
Activity pressure 0.74; No reversal markers Factors32/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 45; Small Cap Core rank 81 SVQF11/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1407.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment55/100Weighted news tone is neutral across 19 relevant articles.
Morepen Lab Consolidated June 2026 Net Sales at Rs 570.13 crore, up 34.07% Y-o-Y Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 80.25 INR | 40.7% | 45.36 INR | 53.03 INR | 1.45 | 76.33 | 329.3M | On |
| 31 Jul 2026 | 57.04 INR | 6.0% | 43.99 INR | 52.74 INR | 1.46 | 28.08 | 24.4M | On |
| 24 Jul 2026 | 53.80 INR | -8.7% | 43.49 INR | 52.57 INR | 1.52 | 23.93 | 31.4M | On |
| 17 Jul 2026 | 58.90 INR | -3.8% | 43.07 INR | 52.42 INR | 1.59 | 32.33 | 48.5M | On |
| 10 Jul 2026 | 61.22 INR | 3.6% | 42.47 INR | 52.23 INR | 1.49 | 38.16 | 56.1M | On |
| 3 Jul 2026 | 59.07 INR | 11.1% | 41.81 INR | 52.02 INR | 1.45 | 33.02 | 9.5M | On |
| 26 Jun 2026 | 53.16 INR | 7.4% | 41.26 INR | 51.84 INR | 1.24 | 20.63 | 0 | On |
| 19 Jun 2026 | 49.50 INR | -1.2% | 40.93 INR | 51.69 INR | 1.18 | 12.26 | 6.2M | On |
| 12 Jun 2026 | 50.12 INR | 14.6% | 40.75 INR | 51.57 INR | 1.12 | 15.08 | 18.2M | On |
| 5 Jun 2026 | 43.75 INR | 1.2% | 40.62 INR | 51.43 INR | 1.00 | 1.05 | 4.9M | On |
| 29 May 2026 | 43.24 INR | 0.8% | 40.73 INR | 51.32 INR | 1.22 | -1.59 | 22.9M | Off |
| 22 May 2026 | 42.91 INR | 2.3% | 40.88 INR | 51.21 INR | 1.20 | -3.81 | 13.6M | Off |
| 15 May 2026 | 41.94 INR | -8.1% | 41.07 INR | 51.10 INR | 1.17 | -6.51 | 20.6M | Off |
| 8 May 2026 | 45.64 INR | 10.3% | 41.28 INR | 51.00 INR | 1.14 | -1.14 | 21.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.